Nobel Prize in Medicine 2026 explained: optogenetics and channelrhodopsin

The 2026 Nobel Prize in Physiology or Medicine is shared equally by Karl Deisseroth (Howard Hughes Medical Institute and Stanford University, USA), Peter Hegemann (Humboldt University of Berlin, Germany) and Georg Nagel (University of Würzburg, Germany) "for their discoveries concerning light-gated ion channels and optogenetics" ([1]). Hegemann and Nagel discovered the protein channelrhodopsin in a single-celled green alga; Deisseroth turned it into a light-controlled switch for nerve cells ([1]). The Nobel Assembly at Karolinska Institutet announced the prize on 5 October 2026 ([1]).

Both prize-winning discoveries by Hegemann and Nagel were made at Max Planck Institutes in Germany — Hegemann's at the Max Planck Institute for Biochemistry in Martinsried, Nagel's at the Max Planck Institute for Biophysics in Frankfurt ([1]).

At a glance

• Laureates: Karl Deisseroth (born 1971), Peter Hegemann (born 1954), Georg Nagel (born 1953), one third each ([1]).
• Citation: "for their discoveries concerning light-gated ion channels and optogenetics" ([1]).
• The discovery: channelrhodopsin, a protein from the alga Chlamydomonas, opens an ion channel when hit by blue light ([1], [3]).
• What came of it: optogenetics — switching defined nerve cells on and off with light, including in the living brain ([1]).
• Prize amount: 12 million Swedish kronor, shared equally ([1]).

From an alga to a light switch

It began with a basic question: how does the single-celled green alga Chlamydomonas reinhardtii swim towards light? Hegemann studied how its eyespot senses light and triggers a rapid electrical response ([1]).

In 2002, Nagel, Hegemann and colleagues described channelrhodopsin-1 as a light-gated proton channel ([2]). In 2003 came channelrhodopsin-2, a cation channel opened directly by light. The team expressed the gene in frog eggs (Xenopus laevis oocytes) and in mammalian cells, and those cells became light sensitive ([3]). That was the decisive finding: the protein works in foreign cells without any other algal proteins ([1], [3]).

In 2005, Deisseroth, together with Edward Boyden, Feng Zhang, Ernst Bamberg and Georg Nagel, introduced the channelrhodopsin-2 gene into rat hippocampal neurons. Brief pulses of blue light fired action potentials with millisecond precision, and only in the cells carrying the gene ([4]). In 2007 the switch worked in the brains of living mice and could change their behaviour; in one study, activating a defined group of hypocretin neurons made sleeping animals wake up sooner ([1], [5]).

What is optogenetics?

Optogenetics combines two tools: genetics, which places a light-sensitive channel protein in one chosen cell type only, and light, which then activates exactly those cells. Unlike an electrode, which excites every cell around it, light acts only where the protein is made ([4]).

For the first time, researchers could test whether a particular group of neurons causes a behaviour, rather than merely being active during it. That was what 20th-century brain research lacked: its maps of the brain showed associations but rarely causes ([1]). Since then, the method has revealed neural circuits behind specific memories, feelings and behaviours that are relevant to neurological and psychiatric disorders ([1]).

What does it mean for medicine?

So far optogenetics is mainly a research tool. It shows which circuits go wrong in disease — a prerequisite for designing more targeted treatments ([1]).

The first steps into the clinic are in ophthalmology. In 2021, Sahel and colleagues reported a patient with advanced retinitis pigmentosa who, after a gene therapy that delivered a light-sensitive channel protein to retinal cells and with special light-stimulating goggles, could again partly perceive and locate objects ([6]). That is a single-patient report from an early trial — proof of principle, not an approved treatment. The Nobel Committee likewise speaks of attempts to restore sight ([1]).

Wider use in humans still faces big hurdles: the gene has to reach the right cells safely and lastingly, and light has to reach the target tissue.

Why it matters

The prize honours a discovery that started from pure curiosity — how an alga senses light — and is now used in laboratories worldwide. It is a textbook example of basic research becoming a method: from the protein (2002/2003) to neurons in a dish (2005) to the living animal (2007) ([1]–[5]).

Sources

1. Nobel Assembly at Karolinska Institutet. Press release: The Nobel Prize in Physiology or Medicine 2026, 5 October 2026: https://www.nobelprize.org/prizes/medicine/2026/press-release/
2. Nagel G, Ollig D, Fuhrmann M, Kateriya S, Musti AM, Bamberg E, Hegemann P. Channelrhodopsin-1: a light-gated proton channel in green algae. Science 2002;296:2395–2398. https://doi.org/10.1126/science.1072068
3. Nagel G, Szellas T, Huhn W, Kateriya S, Adeishvili N, Berthold P, Ollig D, Hegemann P, Bamberg E. Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proc Natl Acad Sci USA 2003;100:13940–13945. https://doi.org/10.1073/pnas.1936192100
4. Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci 2005;8:1263–1268. https://doi.org/10.1038/nn1525
5. Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 2007;450:420–424. https://doi.org/10.1038/nature06310
6. Sahel JA, Boulanger-Scemama E, Pagot C, et al. Partial recovery of visual function in a blind patient after optogenetic therapy. Nat Med 2021;27:1223–1229. https://doi.org/10.1038/s41591-021-01351-4